TABLE 3.
Results from patients in the cross-sectional study
| Patient no. | Proviral HIV-1 DNA (copies/106 PBMC) | Plasma HIV-1 RNA (copies/ml) | No. of cells/mm3
|
CDC stage | Antiretroviral treatmentc | |
|---|---|---|---|---|---|---|
| CD4+ | CD8+ | |||||
| 1 | 8,381 | 194,100 | 335 | 1,927 | B | AZT + 3TC + IDV |
| 2 | 1,456 | 4,960 | 518 | 840 | A | AZT + 3TC |
| 3a | 1,389 | 11,450 | 217 | 591 | B | D4T + 3TC + NVP + NFV |
| 4 | 909 | 17,560 | 441 | 1,053 | B | D4T + 3TC |
| 5 | 783 | 2,570 | 405 | 1,098 | B | D4T + 3TC |
| 6 | 681 | <500 | 472 | 835 | B | D4T + 3TC + IDV |
| 7 | 421 | <500 | 215 | 806 | B | AZT + DDI |
| 8 | 417 | <500 | 157 | 297 | C | AZT + 3TC + IDV |
| 9 | 355 | <500 | 522 | 2,026 | A | AZT + DDI |
| 10 | 217 | <500 | 322 | 306 | B | AZT + 3TC + NFV |
| 11a | 215 | 52,150 | 198 | 1,346 | B | D4T + RTV + SQV |
| 12 | 185 | 4,420 | 456 | 1,253 | B | Untreated |
| 13 | 176 | 5,640 | 642 | 770 | A | Untreated |
| 14 | 154 | <500 | 170 | 911 | B | D4T + 3TC + IDV |
| 15 | 128 | 16,900 | 584 | 749 | A | AZT + 3TC + IDV |
| 16 | 88 | <500 | 621 | 714 | A | D4T + 3TC + NFV |
| 17 | 86 | 41,870 | 134 | 1,181 | C | D4T + 3TC + IDV |
| 18a | 72 | <500 | 553 | 1,317 | C | D4T + 3TC + IDV |
| 19a | 63 | 8,230 | 157 | 594 | B | AZT + 3TC |
| 20a | 49 | <500 | 174 | 1,243 | B | AZT + 3TC + IDV |
| 21b | <10 | 205,360 | 8 | 334 | C | D4T + NVP + NFV |
| Mean ± SD | 773 ± 1,794 | 27,022 ± 59,103 | 348 ± 189 | 961 ± 465 | ||
| Median | 215 | 4,420 | 335 | 840 | ||
a
B subtype.
b
A subtype.
c
Abbreviations: AZT, zidovudine; ddI, didanosine; NVP, nevirapine; NFV, nelfinavir; SQV, saquinavir.